NO300797B1 - Farmasöytisk kombinasjonsformulering inneholdende diltiazem og hydroklortiazid - Google Patents

Farmasöytisk kombinasjonsformulering inneholdende diltiazem og hydroklortiazid Download PDF

Info

Publication number: NO300797B1
Authority: NO; Norway
Prior art keywords: dosage form; solid; oral dosage; diltiazem; form according
Prior art date: 1991-08-12

Application number

NO923127A

Other languages

English (en)

Norwegian (no)

Other versions

NO923127L (no

NO923127D0 (no

Inventor

Ian Richard Buxton

Adrian Brown

Helen Critchley

Stewart Thomas Leslie

Sandra Therese Antoi Malkowska

Derek Allan Prater

Ronald Brown Miller

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-12

Filing date

1992-08-11

Publication date

1997-07-28

1992-08-11 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

1992-08-11 Publication of NO923127D0 publication Critical patent/NO923127D0/no

1993-02-15 Publication of NO923127L publication Critical patent/NO923127L/no

1997-07-28 Publication of NO300797B1 publication Critical patent/NO300797B1/no

Links

HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 title claims description 36
229960004166 diltiazem Drugs 0.000 title claims description 35
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title claims description 26
229960002003 hydrochlorothiazide Drugs 0.000 title claims description 26
239000000203 mixture Substances 0.000 title description 6
238000009472 formulation Methods 0.000 title 1
238000013270 controlled release Methods 0.000 claims description 31
238000000576 coating method Methods 0.000 claims description 27
239000011248 coating agent Substances 0.000 claims description 26
239000000126 substance Substances 0.000 claims description 25
239000006186 oral dosage form Substances 0.000 claims description 20
239000007787 solid Substances 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 17
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
239000004014 plasticizer Substances 0.000 claims description 6
FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 claims description 5
239000001856 Ethyl cellulose Substances 0.000 claims description 5
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
239000011247 coating layer Substances 0.000 claims description 5
229960005316 diltiazem hydrochloride Drugs 0.000 claims description 5
229920001249 ethyl cellulose Polymers 0.000 claims description 5
235000019325 ethyl cellulose Nutrition 0.000 claims description 5
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
239000012528 membrane Substances 0.000 claims description 4
229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
239000008108 microcrystalline cellulose Substances 0.000 claims description 4
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
229940068968 polysorbate 80 Drugs 0.000 claims description 3
229920000053 polysorbate 80 Polymers 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
229920003176 water-insoluble polymer Polymers 0.000 claims description 2
239000011159 matrix material Substances 0.000 description 16
239000002552 dosage form Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000004480 active ingredient Substances 0.000 description 9
229920003086 cellulose ether Polymers 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
229920001515 polyalkylene glycol Polymers 0.000 description 9
229920003134 Eudragit® polymer Polymers 0.000 description 7
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
229920000178 Acrylic resin Polymers 0.000 description 6
239000004925 Acrylic resin Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
229920013820 alkyl cellulose Polymers 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
206010020772 Hypertension Diseases 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000012530 fluid Substances 0.000 description 4
-1 gums Polymers 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
229920001477 hydrophilic polymer Polymers 0.000 description 4
239000001863 hydroxypropyl cellulose Substances 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
238000000034 method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
239000008172 hydrogenated vegetable oil Substances 0.000 description 3
239000010410 layer Substances 0.000 description 3
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
150000002191 fatty alcohols Chemical class 0.000 description 2
239000000499 gel Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol group Chemical group C(CCCCCCCCCCCCCCC)O BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
229920001600 hydrophobic polymer Polymers 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
229920003145 methacrylic acid copolymer Polymers 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
241001440269 Cutina Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
125000005908 glyceryl ester group Chemical group 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
239000012184 mineral wax Substances 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NO923127A 1991-08-12 1992-08-11 Farmasöytisk kombinasjonsformulering inneholdende diltiazem og hydroklortiazid NO300797B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB919117361A GB9117361D0 (en)	1991-08-12	1991-08-12	Oral dosage form

Publications (3)

Publication Number	Publication Date
NO923127D0 NO923127D0 (no)	1992-08-11
NO923127L NO923127L (no)	1993-02-15
NO300797B1 true NO300797B1 (no)	1997-07-28

Family

ID=10699854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO923127A NO300797B1 (no)	1991-08-12	1992-08-11	Farmasöytisk kombinasjonsformulering inneholdende diltiazem og hydroklortiazid

Country Status (14)

Country	Link
US (1)	US5508044A (de)
EP (1)	EP0527638A1 (de)
JP (1)	JPH05201866A (de)
KR (1)	KR930003905A (de)
CN (1)	CN1069191A (de)
AU (1)	AU658209B2 (de)
CA (1)	CA2075355A1 (de)
FI (1)	FI923581A (de)
GB (1)	GB9117361D0 (de)
IL (1)	IL102777A (de)
IN (2)	IN173839B (de)
NO (1)	NO300797B1 (de)
PH (1)	PH30666A (de)
ZA (2)	ZA926020B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9301220D0 (sv) *	1993-04-14	1993-04-14	Kabi Pharmacia Ab	Manufacturing matrices
JPH08143450A (ja) *	1994-11-14	1996-06-04	Taiyo Yakuhin Kogyo Kk	徐放化製剤
US5834024A (en) *	1995-01-05	1998-11-10	Fh Faulding & Co. Limited	Controlled absorption diltiazem pharmaceutical formulation
CN1103592C (zh) *	1996-05-22	2003-03-26	永光制药有限公司	含有2－(苯基亚氨基)－3－苯基－1,3－全氢噻嗪的药物组合物及其应用和制备方法
US6074669A (en) *	1997-01-20	2000-06-13	Ranbaxy Laboratories Limited	Controlled drug delivery system for diltiazem
FR2771291B1 (fr) *	1997-11-21	2000-02-25	Ethypharm Lab Prod Ethiques	Spheroides, procede de preparation et compositions pharmaceutiques
PT1041987E (pt)	1997-12-22	2006-07-31	Euro Celtique Sa	Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
US6524620B2 (en)	1998-07-20	2003-02-25	Andrx Pharmaceuticals, Inc.	Diltiazem controlled release formulation and method of manufacture
US6039979A (en) *	1999-01-13	2000-03-21	Laboratoires Prographarm	Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
FR2794646B1 (fr) *	1999-06-09	2001-09-21	Ethypharm Lab Prod Ethiques	Microgranules de sulfate de morphine, procede de preparation et composition les contenant
US6569456B2 (en) *	2000-01-13	2003-05-27	Osmotica Corp.	Osmotic device containing diltiazem and an ACE inhibitor or diuretic
GB0007419D0 (en) †	2000-03-27	2000-05-17	Smithkline Beecham Gmbh	Composition
GB0025208D0 (en) *	2000-10-13	2000-11-29	Euro Celtique Sa	Delayed release pharmaceutical formulations
EP1387673B1 (de)	2001-05-11	2010-12-29	Endo Pharmaceuticals Inc.	Opioid enthaltende arzneiform gegen missbrauch
ES2733051T1 (es) *	2002-04-05	2019-11-27	Euro Celtique Sa	Matriz para liberación sostenida, invariable e independiente de compuestos activos
AU2003225102A1 (en) *	2002-04-23	2003-11-10	Bristol-Myers Squibb Company	Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2004112756A1 (en)	2003-06-26	2004-12-29	Isa Odidi	Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
SI21637A (sl) *	2003-12-23	2005-06-30	LEK farmacevtska dru�ba d.d.	Farmacevtska oblika z nadzorovanim sproščanjem
EP1604666A1 (de)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
US8394409B2 (en)	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
US10624858B2 (en)	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
US20080096979A1 (en) *	2004-11-08	2008-04-24	Rubicon Research Pvt. Ltd.	Aqueous Pharmaceutical Coating
EP1702558A1 (de)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) *	2006-04-03	2014-03-11	Isa Odidi	Controlled release delivery device comprising an organosol coat
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
CA2671197A1 (en) *	2006-07-21	2008-01-24	Lab International Srl	Hydrophobic abuse deterrent delivery system
CA2703365A1 (en) *	2007-10-25	2009-04-30	Yuka Yamanouchi	Nifedipine-containing press coated tablet and method of preparing the same
MY152279A (en)	2009-03-10	2014-09-15	Euro Celtique Sa	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
BRPI1007636A2 (pt) *	2009-05-01	2015-09-01	Aptalis Pharmatech Inc	Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
GB201003766D0 (en)	2010-03-05	2010-04-21	Univ Strathclyde	Pulsatile drug release
GB201003731D0 (en)	2010-03-05	2010-04-21	Univ Strathclyde	Immediate/delayed drug delivery
GB201003734D0 (en)	2010-03-05	2010-04-21	Univ Strathclyde	Delayed prolonged drug delivery
MY183489A (en)	2013-07-23	2021-02-22	Euro Celtique Sa	A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK152744C (da) *	1982-08-13	1988-10-31	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
IE56999B1 (en) *	1983-12-22	1992-03-11	Elan Corp Plc	Pharmaceutical formulation
US4728512A (en) *	1985-05-06	1988-03-01	American Home Products Corporation	Formulations providing three distinct releases
IT1200217B (it) *	1986-09-30	1989-01-05	Valducci Roberto	Membrana per uso farmaceutico ed industriale
CA1323833C (en) *	1987-04-28	1993-11-02	Yatindra M. Joshi	Pharmaceutical compositions in the form of beadlets and method
IL88083A (en) *	1987-11-06	1992-11-15	Tanabe Seiyaku Co	Controlled release pharmaceutical dosage form and its preparation
FI101344B (fi) *	1988-03-31	1998-06-15	Tanabe Seiyaku Co	Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
JPH0674206B2 (ja) *	1989-12-28	1994-09-21	田辺製薬株式会社	放出制御型製剤およびその製法
US5156850A (en) *	1990-08-31	1992-10-20	Alza Corporation	Dosage form for time-varying patterns of drug delivery
DK0565634T3 (da) *	1990-12-14	1999-09-27	Smithkline Beecham Corp	Angiotensin-II-receptorblokkersammensætninger
US5286497A (en) *	1991-05-20	1994-02-15	Carderm Capital L.P.	Diltiazem formulation

1991
- 1991-08-12 GB GB919117361A patent/GB9117361D0/en active Pending
1992
- 1992-08-04 KR KR1019920013983A patent/KR930003905A/ko not_active Application Discontinuation
- 1992-08-05 IN IN476MA1992 patent/IN173839B/en unknown
- 1992-08-05 CA CA002075355A patent/CA2075355A1/en not_active Abandoned
- 1992-08-05 IN IN475MA1992 patent/IN173847B/en unknown
- 1992-08-06 AU AU20879/92A patent/AU658209B2/en not_active Ceased
- 1992-08-10 IL IL10277792A patent/IL102777A/en not_active IP Right Cessation
- 1992-08-10 PH PH44789A patent/PH30666A/en unknown
- 1992-08-10 JP JP4234294A patent/JPH05201866A/ja active Pending
- 1992-08-11 EP EP19920307334 patent/EP0527638A1/de not_active Ceased
- 1992-08-11 ZA ZA926020A patent/ZA926020B/xx unknown
- 1992-08-11 NO NO923127A patent/NO300797B1/no unknown
- 1992-08-11 ZA ZA926019A patent/ZA926019B/xx unknown
- 1992-08-11 FI FI923581A patent/FI923581A/fi not_active Application Discontinuation
- 1992-08-12 CN CN92109398A patent/CN1069191A/zh active Pending
1994
- 1994-07-22 US US08/279,062 patent/US5508044A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ZA926020B (en)	1993-03-10
IN173847B (de)	1994-07-23
EP0527638A1 (de)	1993-02-17
NO923127L (no)	1993-02-15
CN1069191A (zh)	1993-02-24
US5508044A (en)	1996-04-16
CA2075355A1 (en)	1993-02-13
FI923581A (fi)	1993-02-13
PH30666A (en)	1997-09-16
GB9117361D0 (en)	1991-09-25
IL102777A (en)	1996-05-14
AU2087992A (en)	1993-02-18
NO923127D0 (no)	1992-08-11
KR930003905A (ko)	1993-03-22
JPH05201866A (ja)	1993-08-10
IN173839B (de)	1994-07-23
FI923581A0 (fi)	1992-08-11
AU658209B2 (en)	1995-04-06
ZA926019B (en)	1993-03-10
IL102777A0 (en)	1993-01-31

Publication	Publication Date	Title
NO300797B1 (no)	1997-07-28	Farmasöytisk kombinasjonsformulering inneholdende diltiazem og hydroklortiazid
EP0527637B1 (de)	1998-04-29	Sphäroide enthaltend Diltiazem und Sphäronisierungsmittel
US4772475A (en)	1988-09-20	Controlled-release multiple units pharmaceutical formulation
KR100348585B1 (ko)	2002-10-31	다리페나신을함유하는약학제제
US20040052844A1 (en)	2004-03-18	Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
JP2004107351A (ja)	2004-04-08	有効成分を徐放するための多層マトリックス系
JP2004530676A (ja)	2004-10-07	持続放出性薬学的組成物のための新規コーティング
ZA200101485B (en)	2002-02-22	Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same.
EP0211991B1 (de)	1989-10-25	Tabletten mit verzögerter Freisetzung sowie Verfahren zu deren Herstellung
JP2009543791A (ja)	2009-12-10	即放性形態および徐放性形態のトラマドールを有するマルチパーティキュレート処方物
CN102046155A (zh)	2011-05-04	包含多颗粒的具有双重释放特性的固体口服剂型
JPH082783B2 (ja)	1996-01-17	新規な投与形態
WO2020157730A1 (en)	2020-08-06	A controlled release pharmaceutical composition of selexipag or it's active metabolite
CZ2006269A3 (cs)	2006-07-12	Pelety obsahující hydrochlorid venlafaxinu
JPH02501744A (ja)	1990-06-14	ブスピロンおよびその塩の経口投与用組成物
NO331480B1 (no)	2012-01-16	Farmasoytiske sammensetninger med kontrollert frigivelse
WO2005102272A2 (en)	2005-11-03	Sustained-release dosage forms for cabergoline
WO2021111419A1 (en)	2021-06-10	Modified release pharmaceutical compositions of riociguat
EP3892263A1 (de)	2021-10-13	Orale darreichungsform
GB2258810A (en)	1993-02-24	Pharmaceutical combination formulation of diltiazem and hydrochlorothiazide
CN106511293A (zh)	2017-03-22	含有达方吡啶的缓释口服制剂及其用途
JPH024575B2 (de)	1990-01-29
JP3004663B2 (ja)	2000-01-31	徐放性フレカイニドアセテート製剤
GB2258613A (en)	1993-02-17	Pharmaceutical diltiazem spheroid formulation